544 terminated. 544 Phase 1, 189 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 544 | Terminated 544 |
| Phase 2 | 189 | Terminated 189 |
Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL Antigen-specific T cells CAR-T/CTL and DCvac - T-Cell Acute Lymphoblastic Leukemia | Phase 1 | Terminated | Shenzhen Geno-Immune Medical Institute | 10 | 2026-06-01 | 2026-11-03 |
| Multiple CAR-T Cell Therapy Targeting AML CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 10 | 2025-08-01 | 2026-11-02 |
| Combination CAR-T Cell Therapy Targeting Hematological Malignancies 4SCAR19 and 4SCAR22, 4SCAR19 and 4SCAR38, 4SCAR19 and 4SCAR20 - B-cell Malignancies | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2025-08-01 | 2026-10-30 |
| A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia CD19 t-haNK - B-ALL, Leukemia | Phase 1 | Terminated | ImmunityBio, Inc. | 4 | 2025-04-11 | 2026-08-19 |
| A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML S227928, Venetoclax - Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML | Phase 1 / Phase 2 | Terminated | Servier Bio-Innovation LLC | 13 | 2025-02-25 | 2026-03-30 |
| BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS SOC + BSB-1001 Dose Escalation Cohort, SOC+BSB-1001 Expansion Dose - AML, Adult Recurrent, ALL, Recurrent, Adult | Phase 1 / Phase 2 | Terminated | BlueSphere Bio, Inc | 2 | 2025-02-04 | 2026-09-10 |
| Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1 BL-M11D1 - Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Terminated | SystImmune Inc. | 52 | 2024-12-19 | 2026-09-24 |
| A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1) AUR104 - Select Relapsed/Refractory Lymphoid Malignancies | Phase 1 | Terminated | Aurigene Discovery Technologies Limited | 9 | 2024-12-12 | 2026-04-17 |
| Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) Venetoclax, Azacitidine, Donor Lymphocyte Infusion - Acute Myeloid Leukemia | Phase 1 | Terminated | Antonio M Jimenez Jimenez | 2 | 2024-12-04 | 2026-07-13 |
| Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML Luveltamab tazevibulin - Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Terminated | Sutro Biopharma, Inc. | 1 | 2024-12-04 | 2026-10-13 |
| Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-26 | 2025-08-03 |
| Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] NP137, Azacitidine Injection, Venetoclax - Acute Myeloid Leukemia Refractory | Phase 1 / Phase 2 | Terminated | Centre Leon Berard | 1 | 2024-09-11 | 2025-02-20 |
| Study of Tazemetostat in Lymphoid Malignancies Tazemetostat - T-cell Lymphoma | Phase 1 | Terminated | University of Alabama at Birmingham | 6 | 2024-09-05 | 2026-04-17 |
| A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies SAR443579, venetoclax, azacitidine - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Sanofi | 7 | 2024-08-13 | 2026-10-19 |
| Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome BMS-986497, Azacitidine, Venetoclax - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Terminated | Bristol-Myers Squibb | 34 | 2024-05-29 | 2026-10-01 |
| CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia CB-012 - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 | Terminated | Caribou Biosciences, Inc. | 12 | 2024-02-08 | 2025-06-11 |
| Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant VCAR33 - Leukemia, Myeloid, Acute | Phase 1 / Phase 2 | Terminated | Vor Biopharma | 38 | 2023-12-11 | 2025-07-29 |
| Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML Dose Escalation -tagraxofusp-erzs, Dose Expansion at RP2D -tagraxofusp-erzs - Acute Myeloid Leukemia | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 7 | 2023-11-20 | 2026-06-25 |
| Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes KPT-8602, Inqovi, Bone marrow aspirate - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 3 | 2023-11-14 | 2025-12-02 |
| Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) ABBV-787 - Acute Myeloid Leukemia | Phase 1 | Terminated | AbbVie | 36 | 2023-11-13 | 2025-03-06 |
Showing 20 of 544. Sign in to see all of them.
Leukemia, Myeloid, Acute (289) · Leukemia, Lymphocytic, Chronic, B-Cell (154) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (132) · Myelodysplastic Syndromes (107) · Lymphoma, Non-Hodgkin (89) · Recurrence (73) · Lymphoma (66) · Lymphoma, Large B-Cell, Diffuse (64) · Lymphoma, Mantle-Cell (61) · Lymphoma, Follicular (59) · Burkitt Lymphoma (51) · Lymphoma, B-Cell, Marginal Zone (49) · Multiple Myeloma (48) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (42)
Hemic and Lymphatic Diseases (544) · Neoplasms by Histologic Type (541) · Hematologic Diseases (538) · Neoplasms (511) · Leukemia, Myeloid (318) · Immune System Diseases (290) · Immunoproliferative Disorders (287) · Lymphoproliferative Disorders (282) · Pathological Conditions, Signs and Symptoms (281) · Lymphatic Diseases (280) · Pathologic Processes (280) · Disease Attributes (275) · Leukemia, Lymphoid (247) · Chronic Disease (228)
Cytarabine (55) · Azacitidine (47) · Cyclophosphamide (44) · venetoclax (43) · fludarabine (39) · Rituximab (33) · fludarabine phosphate (26) · Decitabine (16) · Filgrastim (16) · Lenalidomide (16) · Dexamethasone (15) · Methotrexate (15) · Etoposide (14) · Dasatinib (13) · Mitoxantrone (12)
M.D. Anderson Cancer Center (44) · National Cancer Institute (NCI) (41) · Masonic Cancer Center, University of Minnesota (11) · Novartis Pharmaceuticals (11) · Gilead Sciences (10) · Fred Hutchinson Cancer Center (9) · AbbVie (8) · Northwestern University (8) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (8) · Celgene (7) · Amgen (6) · Bristol-Myers Squibb (6) · Incyte Corporation (6) · Merck Sharp & Dohme LLC (6) · Therapeutic Advances in Childhood Leukemia Consortium (6)
United States (456) · Spain (53) · France (50) · Canada (40) · Germany (37) · Italy (36) · Australia (30) · China (24) · Netherlands (22) · United Kingdom (22) · Belgium (17) · Israel (15) · Japan (13) · South Korea (13) · Poland (11)
Roger Strair, MD, PhD (4) · Farhad Ravandi-Kashani, MD (3) · Abhinav Deol, M.D. (2) · Ajay Gopal (2)
PMID 31527168, PMID 33197925, PMID 34398557, PMID 36841672, PMID 17151364, PMID 19010875, PMID 19029442, PMID 19139736, PMID 19503090, PMID 20460644, PMID 20563869, PMID 21145590, PMID 21494838, PMID 22080968, PMID 22448921, PMID 22987312, PMID 23092873, PMID 23233571, PMID 23256542, PMID 23393050, PMID 23400739, PMID 23887852, PMID 24200998, PMID 24241210, PMID 24276047, PMID 24355079, PMID 24615776, PMID 24615777, PMID 24615778, PMID 25441108, PMID 26472751, PMID 27118540, PMID 27544076, PMID 28161120, PMID 28280089, PMID 29042364, PMID 29141948, PMID 29142066, PMID 29296751, PMID 29296805, PMID 29339097, PMID 29432154, PMID 29610115, PMID 30361262, PMID 30444200, PMID 30559424, PMID 30962222, PMID 31235963, PMID 31443741, PMID 31471376
2018 (11), 2017 (8), 2023 (8), 2019 (6), U01CA076576 (6), 2014 (5), 2015 (4), P30CA015083 (4), P30CA015704 (4), P30CA016672 (4), P30CA072720 (4), 2016 (3), P01CA018029 (3), P30CA006973 (3), P30CA016058 (3)